Novocure Receives FDA Approval for Second Generation Optune System Second generation Optune system is less than half the weight and size of first generation Optune system New system aims to make ...
The FDA has approved a lighter and more convenient version of the tumor-treating field device Optune for patients with glioblastoma multiforme. The FDA has approved a lighter and more convenient ...
ST. HELIER, Jersey--(BUSINESS WIRE)--Before starting treatment with Optune in October 2015, Michael Olson, 39, of Beaumont, Texas, worried about how he’d incorporate the treatment into his life and ...
ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that the State of Israel Ministry of Health has added Optune in combination with temozolomide to the Israeli medical ...
ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have released a final local ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The approval was based on findings from the phase 3 EF-14 trial. The FDA has expanded the indication for Optune (NovoTTF-100A System) in combination with Temodar (temozolomide) as a treatment for ...
The glut of data released at the AACR meeting on Novocure’s (NVCR) Optune device in various hard-to-treat cancers has caused the company’s shares to pop by 37%. The system, which emits electric fields ...
SHREVEPORT, La. (Press Release) - Willis-Knighton Cancer Center is now offering Optune, a medical device that, when used in conjunction with partial-brain radiotherapy and chemotherapy, has been shown ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results